We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.
Gérard Klop
Advertisement
Partner, Vintura
Articles by Gérard Klop
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Sends Amended Acquisition Proposal to Metsera
2
Pharmaceutical Executive Daily: Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue
3
FDA Approves Kygevvi Becoming the First Treatment for Thymidine Kinase 2 Deficiency
4
Roundup: Pharma Industry Forms Strategic Collaborations Bolstering Research and Development Pipelines for Autoimmune and Oncology Therapies
5
